Thanks sb - I am pretty sure that the CEO did advise in some of his presentations that we would be concentrating on the high value areas. I am interested to know though if we are still considering the other options such as Dura Mater Repair, Stem Cell delivery and Abdominal Surgery. There has been no mention of them in recent announcements. Below is an old (2015) timetable -
REGENERATIVE TISSUE PRODUCT PORTFOLIO -
Congenital Heart Disease (CHD) - Launched in EU & US
Cardiovascular Applications Heart valve repairs & reconstructions*- On market in US & Asia Vascular tissue Carotid Endarterectomy (CEA) - On market in 2016
Dura mater repair Spinal and cranial repair - File 2017
Whole vascular tissue CABG, AV fistula - File 2018
Stem Cell or stem cell factor delivery ADAPT tissue with stem cells - File/partner 2019
Abdominal surgery Hernia repairs -File 2020 ADAPT® *
AHZ Price at posting:
25.0¢ Sentiment: Buy Disclosure: Held
(20min delay)